(Q34273302)

English

Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

author name string

S M Poucher

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S Cheetham

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J Francis

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

B Zinker

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M Kirby

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S P Vickers

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

28 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

918-926

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Fate of the beta-cell in the pathophysiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Oral antidiabetic agents in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Exploration of the DPP-4 inhibitors with a focus on saxagliptin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Sulfonylurea induced beta-cell apoptosis in cultured human islets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Nongenetic mouse models of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Type 2 diabetes-a matter of beta-cell life and death?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Preservation of beta-cell function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01619.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01619.X

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34273302&oldid=1544779015"